Skip to main content

Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira® is a registered trademark of AbbVie Biotechnology Ltd.

Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira® is a registered trademark of AbbVie Biotechnology Ltd.

October 10

October 10, 2019
London, UK

ISOPP

International Society of Oncology Pharmacy Practicioners, October 10 - 13 2019

NEXT EVENT

October 09

October 09, 2019
Madrid, Spain

EADV

European Academy of Dermatology and Venerology, October 9 - 13 2019

NEXT EVENT

October 08

October 08, 2019
Hong Kong, China

PENSA

The Parenteral and Enteral Nutrition Society of Asia, October 8 - 10 2019

NEXT EVENT

September 27

September 27, 2019
Barcelona, Spain

ESMO

European Society for Medical Oncology, September 27 - October 1 2019

NEXT EVENT

September 25

September 25, 2019
Krakow, Poland

EUGMS

International Congress of the European Geriatric Medicine Society, September 25 - 27 2019

NEXT EVENT

Leucovorin Calcium is the newest addition to the company’s large oncology portfolio.

September 19

September 19, 2019
Vienna, Austria

ESSD

European Society for Swallowing Disorders, September 19 - 21 2019

NEXT EVENT

August 31

August 31, 2019
Krakow, Poland

ESPEN

European Society for Clinical Nutrition and Metabolism, August 31 - September 3 2019

NEXT EVENT

Subscribe to